Voyager Therapeutics to Participate in Upcoming Investor Conferences
Get Alerts VYGR Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies, today announced that it will participate in the following upcoming virtual investor conferences.
- Wedbush PacGrow Healthcare Conference, panel discussion, August 11, 2021, 8:35 AM ET.
- Canaccord Genuity Growth Conference, fireside chat, August 12, 2021, 10:30-10:55 AM ET.
The sessions may be accessed from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. Replays of the webcasts will be archived on the Company's website for at least 30 days.
About Voyager TherapeuticsVoyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the technology to treat devastating diseases. Proprietary capsids born from the Company’s TRACER™ screening platform are powering a rich early-stage pipeline of new and second-generation programs and may elevate the field to overcome the limitations of conventional gene therapy vectors across neurological disorders and other therapeutic areas.
voyagertherapeutics.com LinkedIn Twitter
Investor Inquiries: [email protected]
Media Inquiries: Scott Santiamo[email protected]
Source: Voyager Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Flotek Industries, Inc. (NYSE: FTK); Hub Group, Inc. (NASDAQ: HUBG); and Insulet Corporation (NASDAQ: PODD): G
- XO Sports Xplodes into the USA
- Sandman Sports Launches The Edge, an AI-Powered Prediction Engine Built to Help Bettors Find Value, Not Just Picks
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Twitter, Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share